Pharma and medical imaging company MedTrace has appointed Nicholas Borys, MD, as Chief Medical Officer (CMO).
Borys has over 25 years of experience in executive roles in the healthcare sector. He led drug development at Imunon, Amersham, and Hoffmann-La Roche, and successfully led and completed four new drug applications. He joins MedTrace after having spent the last two years as a consulting chief medical officer at NB&C Consulting.
Nicholas Borys, MD.MedTrace
At MedTrace, he will be responsible for the completion of the company's phase III clinical trial assessing the diagnostic accuracy and safety of oxygen-15 labeled water as a myocardial perfusion PET imaging agent. Borys will also lead the company's clinical, regulatory, and medical affairs departments.
